x

Rechercher un essai clinique

* (*) Champ obligatoire

10 Résultat(s)

Essai en cours de recrutement = Essai en cours de recrutement; Essai en cours = Essai en cours; Financé par un membre IRDiRC = ; Membre d'un ERN =

Essai(s) clinique(s) national(aux)

ROYAUME-UNI

Greater London
LONDON

CMT-TRAUK: Randomised double blind placebo controlled trial of long term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (Phase III) (Completed)
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)

ROYAUME-UNI

Greater London
LONDON

PADIMAC: Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT - UK
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)

ROYAUME-UNI

Greater London
LONDON

Bortezomib Consolidation Trial: A Phase II study of bortezomib consolidation after high dose therapy and autologous stem cell transplantation for multiple myeloma - UK
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)

ROYAUME-UNI

Greater London
LONDON

Essai en coursAn Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies-GB
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)

ROYAUME-UNI

Greater London
LONDON

Essai en coursFinancé par un membre IRDiRCPhase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM) - GB
UCL Institute of Neurology, University College London,
Clinical Neurosciences

ROYAUME-UNI

Greater London
LONDON

Essai en cours de recrutementEssai en coursCOBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
University College London Hospitals NHS Foundation Trust
Cancer Division